ClinicalTrials.gg
Active, not recruitingNCT05466786Updated Oct 19, 2026

Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer

An observational study in Breast Cancer and HER2-low Breast Cancer, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

Updated Oct 19, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
255
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 59 open to participants now, 67 under way, 18 of them phase 3. Breast Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Planned enrollment
14th of 29
255 · median 220
Started
2022
with 10 others
Observational
29 of 101
11 open now
Primary completion
2028-12
later than 43 of 66 live
Registered
37th of 101
by date

Among the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 14th largest by planned enrollment of the 29 observational ones that give a count, is one of 11 that started in 2022, is one of 29 observational ones, reaches primary completion later than 43 of the 66 other live ones, and was the 37th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

59 of the 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

54 more — sign in →

By country, each count listing its studies:

All 59 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, or all of them as a file.
02

Study summary

This is a cross-sectional and an observational study, investigator-initiated study in HER2-low breast cancer patients. Approximately 255 subjects with HRD (homologous recombination deficiency) assessment will be enrolled in this study to examine the distribution and features of HRD/HRR (homologous recombination repair).

In this study, investigators plan to clarify the frequency of HRR/HRD in Chinese patients with HER2-low breast cancer.

In addition, it is planned to investigate any association between invasive disease-free survival (iDFS)/overall survival (OS) and HRD/HRR in HER2-low breast cancer patients.

03

Conditions studied

  • Breast Cancer
  • HER2-low Breast Cancer

Browse trials for

Keywords

  • Homologous recombination-related
  • Homologous recombination deficiency
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female patients aged 18-70 years with pathologically confirmed HER2-low breast cancer (defined as IHC 2+/ISH- or IHC 1+ per ASCO/CAP guidelines)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged 18-70 years with confirmed -low breast cancer (defined as IHC 2+/ISH- or IHC 1+ per ASCO/CAP guidelines);
  2. performance status of 0 or 1;
  3. Treatment-naïve operable primary breast cancer with completed homologous recombination deficiency (HRD) assessment;

5)Absence of distant ; 6)Availability of adequate tumor tissue and blood samples for biomarker analysis.

Exclusion criteria

Exclusion Criteria:

  1. Recurrent or inoperable locally advanced breast cancer;
  2. Bilateral breast cancer;
  3. History of other malignant tumors within the past 5 years;
  4. Incomplete clinical or pathological data.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
255 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Experimental ARM

    All patients received standard care for postoperative management.

    Other: Standard Management

Interventions

  • OtherStandard Management

    Standard Management

06

What researchers measure

Primary outcomes

  1. 1.To assess the distribution characteristics of mHRR/HRD in breast cancer with low HRE2 expression in Chinese population

    the distribution and features of HRD /HRR is evaluated.

    Time frame: At the time of 4 weeks after surgery

Secondary outcomes

  1. To assess the clinical characteristics between patients with mutations and non-mutation

    Association between mutations and non-mutations group in HRD/HRR is assessed.

    Time frame: At the time of 4 weeks after surgery

  2. To compare the correlation between iDFS/OS and different adjuvant treatment regimens for breast cancer with low HER2 expression

    IDFS, was a composite endpoint defined as the time from enrollment until the date of the first occurrence of one of the following events: Ipsilateral invasive breast cancer recurrence (same breast); Ipsilateral (same side of body) local regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and/or skin); Distant recurrence (evidence of breast cancer in any anatomic site); Death attributable to any cause; Contralateral (opposite side of the body) invasive breast cancer. 3-year Overall survival (OS) was defined as time from date of randomization to death from any cause, otherwise cases were censored at date last known to be alive. Association between IDFS/OS and HRD/HRR information is evaluated.

    Time frame: At the time of 36 months after surgery

  3. To investigate the HRR/HRD characteristics and clinical characteristics (family history, age pathological feature es, etc.) of breast cancer patients with low HER2 expression

    Association between multivariate prognostic factors and survival is evaluated.

    Time frame: At the time of 4 weeks after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2028, 76 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 76 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion May 2027 → Dec 2028 and completion May 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2022
First posted
Jul 20, 2022
StartActual
Aug 7, 2022
Primary completionEst.
Dec 31, 2028was May 2027
CompletionEst.
Dec 31, 2028was May 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 19, 2026
Primary completion
May 31, 2027→Dec 31, 2028
Oct 19, 2026
Study completion
May 31, 2027→Dec 31, 2028
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Active, not recruiting
    Primary completion May 31, 2027→Dec 31, 2028
    Study completion May 31, 2027→Dec 31, 2028
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05466786
Responsible party
Chang Gong (Chief physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jul 20, 2022
Start date
Aug 7, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Gong Chang, doctor
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion